Lund Melanoma Study Group
1 – 10 of 277
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Comment on ‘Contrasting survival outcomes and patient characteristics in 5815 patients with stage II and III melanoma : a nationwide population-based registry study from Sweden’: reply from the authors
- Contribution to journal › Letter
-
Mark
Sex Differences in Loss in Life Expectancy in Primary Cutaneous Melanoma, a Swedish Cohort Study
- Contribution to journal › Article
-
Mark
The FOCU.SE trial : a nationwide Swedish drug repurposing protocol and research framework
- Contribution to journal › Letter
-
Mark
The Effects of Sun Exposure and Pigmentation Phenotype on Prognosis in Metastatic Melanoma
- Contribution to journal › Article
-
Mark
Assessment of high- and low-risk histopathologic subtypes of basal cell carcinoma using artificial intelligence and dermatologist evaluation
- Contribution to journal › Article
-
Mark
Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III–IV melanoma : A retrospective cohort study
- Contribution to journal › Article
-
Mark
Evaluating COVID-19 Pandemic Impact on Melanoma Incidence and factors in Regions with Different Infection Control Strategies
(2026) In The British journal of dermatology
- Contribution to journal › Article
-
Mark
Desmoplastic melanoma in Sweden in 2009–2022 : A population-based registry study demonstrating distinctive tumour characteristics, incidence and survival trends
- Contribution to journal › Article
-
Mark
Contrasting Survival Outcomes and Patient Characteristics in 5,815 Patients with Stage II and III Melanoma : A Nationwide Population-Based Registry Study from Sweden
- Contribution to journal › Article
-
Mark
Systemic and local decorin levels mirror the clinical course of pancreatic cancer
- Contribution to journal › Article
